Cherinne Arundel1, Phillip H Lam2, Gauravpal S Gill3, Samir Patel4, Gurusher Panjrath5, Charles Faselis6, Michel White7, Charity J Morgan8, Richard M Allman5, Wilbert S Aronow9, Steven N Singh10, Gregg C Fonarow11, Ali Ahmed12. 1. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC; Department of Medicine, Georgetown University, Washington, DC. 2. Department of Medicine, Georgetown University, Washington, DC; Department of Medicine, MedStar Washington Hospital Center, Washington, DC; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, MedStar Washington Hospital Center, Washington, DC. 4. Medical Service, Veterans Affairs Medical Center, Washington, DC. 5. Department of Medicine, George Washington University, Washington, DC. 6. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC. 7. Department of Medicine, University of Montreal and Montreal Heart Institute, Montreal, Quebec, Canada. 8. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama. 9. Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, New York. 10. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, Georgetown University, Washington, DC. 11. Department of Medicine, University of California, Los Angeles, California. 12. Medical Service, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC; Department of Medicine, Georgetown University, Washington, DC. Electronic address: ali.ahmed@va.gov.
Abstract
BACKGROUND: National guidelines recommend that systolic blood pressure (SBP) in patients with heart failure with reduced ejection fraction (HFrEF) and hypertension be maintained below 130 mm Hg. OBJECTIVES: This study sought to determine associations of SBP <130 mm Hg with outcomes in patients with HFrEF. METHODS: Of the 25,345 patients in the Medicare-linked OPTIMIZE-HF registry, 10,535 had an ejection fraction (EF) ≤40%. Of these, 5,615 had stable SBP (≤20 mm Hg admission to discharge variation), and 3,805 (68%) had a discharge SBP <130 mm Hg. Propensity scores for SBP <130 mm Hg, estimated for each of the 5,615 patients, were used to assemble a matched cohort of 1,189 pairs of patients with SBP <130 versus ≥130 mm Hg, balanced on 58 baseline characteristics (mean age 76 years; mean EF 28%, 45% women, 13% African American). This process was repeated in 3,946 patients, after excluding 1,669 patients (30% of 5,615) with a discharge SBP <110 mm Hg and assembled a second matched balanced cohort of 1,099 pairs of patients with SBP 110 to 129 mm Hg versus ≥130 mm Hg. RESULTS: Thirty-day all-cause mortality occurred in 7% and 4% of matched patients with SBP <130 mm Hg versus ≥130 mm Hg, respectively (hazard ratio [HR]: 1.76; 95% confidence interval [CI]: 1.24 to 2.48; p = 0.001). HRs (95% CIs) for all-cause mortality, all-cause readmission, and HF readmission at 1 year, associated with SBP <130 mm Hg, were 1.32 (1.15 to 1.53; p < 0.001), 1.11 (1.01 to 1.23; p = 0.030), and 1.24 (1.09 to 1.42; p = 0.001), respectively. HRs (95% CIs) for 30-day and 1-year all-cause mortality associated with SBP 110 to 129 mm Hg (vs. ≥130 mm Hg) were 1.50 (1.03 to 2.19; p = 0.035), and 1.19 (1.02 to 1.39; p = 0.029), respectively. CONCLUSIONS: Among hospitalized older patients with HFrEF, SBP <130 mm Hg is associated with poor outcomes. This association persisted when the analyses were repeated after excluding patients with SBP <110 mm Hg. There is an urgent need for randomized controlled trials to evaluate optimal SBP reduction goals in patients with HFrEF. Published by Elsevier Inc.
BACKGROUND: National guidelines recommend that systolic blood pressure (SBP) in patients with heart failure with reduced ejection fraction (HFrEF) and hypertension be maintained below 130 mm Hg. OBJECTIVES: This study sought to determine associations of SBP <130 mm Hg with outcomes in patients with HFrEF. METHODS: Of the 25,345 patients in the Medicare-linked OPTIMIZE-HF registry, 10,535 had an ejection fraction (EF) ≤40%. Of these, 5,615 had stable SBP (≤20 mm Hg admission to discharge variation), and 3,805 (68%) had a discharge SBP <130 mm Hg. Propensity scores for SBP <130 mm Hg, estimated for each of the 5,615 patients, were used to assemble a matched cohort of 1,189 pairs of patients with SBP <130 versus ≥130 mm Hg, balanced on 58 baseline characteristics (mean age 76 years; mean EF 28%, 45% women, 13% African American). This process was repeated in 3,946 patients, after excluding 1,669 patients (30% of 5,615) with a discharge SBP <110 mm Hg and assembled a second matched balanced cohort of 1,099 pairs of patients with SBP 110 to 129 mm Hg versus ≥130 mm Hg. RESULTS: Thirty-day all-cause mortality occurred in 7% and 4% of matched patients with SBP <130 mm Hg versus ≥130 mm Hg, respectively (hazard ratio [HR]: 1.76; 95% confidence interval [CI]: 1.24 to 2.48; p = 0.001). HRs (95% CIs) for all-cause mortality, all-cause readmission, and HF readmission at 1 year, associated with SBP <130 mm Hg, were 1.32 (1.15 to 1.53; p < 0.001), 1.11 (1.01 to 1.23; p = 0.030), and 1.24 (1.09 to 1.42; p = 0.001), respectively. HRs (95% CIs) for 30-day and 1-year all-cause mortality associated with SBP 110 to 129 mm Hg (vs. ≥130 mm Hg) were 1.50 (1.03 to 2.19; p = 0.035), and 1.19 (1.02 to 1.39; p = 0.029), respectively. CONCLUSIONS: Among hospitalized older patients with HFrEF, SBP <130 mm Hg is associated with poor outcomes. This association persisted when the analyses were repeated after excluding patients with SBP <110 mm Hg. There is an urgent need for randomized controlled trials to evaluate optimal SBP reduction goals in patients with HFrEF. Published by Elsevier Inc.
Authors: Leah Rethy; Thanh-Huyen T Vu; Nilay S Shah; Mercedes R Carnethon; Tara Lagu; Mark D Huffman; Clyde W Yancy; Donald M Lloyd-Jones; Sadiya S Khan Journal: Circ Heart Fail Date: 2022-04-28 Impact factor: 10.447
Authors: Xiao Gu; Dong D Wang; Teresa T Fung; Dariush Mozaffarian; Luc Djoussé; Bernard Rosner; Frank M Sacks; Walter C Willett Journal: Am J Clin Nutr Date: 2022-08-04 Impact factor: 8.472
Authors: Johannes Grand; Kristina Miger; Ahmad Sajadieh; Lars Køber; Christian Torp-Pedersen; Georg Ertl; José López-Sendón; Aldo Pietro Maggioni; John R Teerlink; Naoki Sato; Claudio Gimpelewicz; Marco Metra; Thomas Holbro; Olav W Nielsen Journal: J Am Heart Assoc Date: 2021-09-13 Impact factor: 5.501
Authors: Christoph Fisser; Jannis Bureck; Lara Gall; Victoria Vaas; Jörg Priefert; Sabine Fredersdorf; Florian Zeman; Dominik Linz; Holger Wöhrle; Renaud Tamisier; Helmut Teschler; Martin R Cowie; Michael Arzt Journal: ERJ Open Res Date: 2021-08-02
Authors: Charles Faselis; Cherinne Arundel; Samir Patel; Phillip H Lam; Stephen S Gottlieb; Michael R Zile; Prakash Deedwania; Gerasimos Filippatos; Helen M Sheriff; Qing Zeng; Charity J Morgan; Samuel Wopperer; Tran Nguyen; Richard M Allman; Gregg C Fonarow; Ali Ahmed Journal: J Am Coll Cardiol Date: 2020-08-11 Impact factor: 27.203
Authors: Yan Cheng; Ali Ahmed; Edward Zamrini; Debby W Tsuang; Helen M Sheriff; Qing Zeng-Treitler Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Charles Faselis; Phillip H Lam; Michael R Zile; Poonam Bhyan; Apostolos Tsimploulis; Cherinne Arundel; Samir Patel; Peter Kokkinos; Prakash Deedwania; Deepak L Bhatt; Qing Zeng-Trietler; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Gregg C Fonarow; Ali Ahmed Journal: Am J Med Date: 2020-09-30 Impact factor: 4.965